Abiraterone Acetate NDC 51407-503

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-503Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0503Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-503-12	51407050312	120 TABLET in 1 BOTTLE, PLASTIC (51407-503-12)Marketed from Sep 4, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Abiraterone Acetate
Generic name (nonproprietary): abiraterone acetate
Active ingredients: Abiraterone acetate — 125 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 210308
Marketing start: May 22, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 17A1 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)
Identifiers: Product ID 51407-503_5467687f-51ac-1f50-e063-6394a90ab3f7SPL ID 5467687f-51ac-1f50-e063-6394a90ab3f7SPL set ID 445e70a1-25bd-8fc1-e063-6394a90a1a43RxCUI 2046579UNII EM5OCB9YJ6
Pharmacologic class: Cytochrome P450 17A1 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407050312 followed by a unit qualifier and the quantity

Package 51407-0503-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 16, 2026.

Indications (excerpt from the label)

Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 210308

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 210308
Product	Strength	Form · route	Labeler	Product NDC
Yonsaabiraterone acetate	Abiraterone acetate 125 mg/1	TabletOral	Sun Pharmaceutical Industries, Inc.	47335-401